Imunopharm’s IM19 CAR‑T Wins NMPA IND for Second‑Line NHL Therapy
Beijing Imunopharm Technology Co., Ltd. announced that its independently developed CD19‑targeted CAR‑T cell therapy, IM19,...
InduPro Partners with Lilly on $950M Oncology Deal Using Proximity-Guided Platform
InduPro announced a global strategic collaboration, licensing agreement, and equity investment with Eli Lilly (NYSE:...
MediLink Licenses B7H3 ADC YL201 to Roche in $850 Million Global Deal
MediLink Therapeutics announced a collaboration and exclusive licensing agreement with Roche (SWX: ROG, OTCMKTS: RHHBY)...
Shanghai MicuRx’s Contezolid Patent Extended Through 2033, Securing Market Exclusivity
Shanghai MicuRx Pharmaceutical Co., Ltd (SHA: 688373) announced that the patent for its core product,...
Lilly’s Taltz-Zepbound Combo Meets Primary Endpoint in Psoriatic Arthritis
Eli Lilly (NYSE: LLY) announced positive topline results from the TOGETHER‑PsA open‑label Phase 3b trial evaluating...
NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight
The National Medical Products Administration (NMPA) issued the “Announcement on Strengthening Supervision and Management of...
Betta Pharmaceuticals Partners with Westlake University on Pharma Innovation
Betta Pharmaceuticals Co., Ltd. (SHE: 300558) and Westlake University announced a strategic partnership to advance...
Viva Biotech and CMS Forge AI-Powered Drug Development Alliance
Viva Biotech (HKG: 1873) and China Medical System Holdings Limited (CMS; HKG: 0867, SGX: 8A8)...
Hisun and ECNU Forge AI Drug Discovery Partnership
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA: 600267) and East China Normal University (ECNU) announced a...
NMPA Issues Priority Review Guidelines for Clinically Urgent Overseas Drugs
The National Medical Products Administration (NMPA) issued Announcement No. 3, 2026 on further optimizing the review...
Sciclon Licenses Augtyro Promotion Rights from Zai Lab for China Market
Sciclon Pharmaceuticals (HKG: 6600) forged a collaboration with Zai Lab (NASDAQ: ZLAB, HKG: 9688), securing exclusive promotional rights...
Hengrui’s Retlirafusp α Wins NMPA Approval for First-Line Gastric Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276, HKG: 1276) announced that its self-developed Category 1 drug,...
Pfizer Partners with Cartography on $850 Million Tumor Antigen Discovery Deal
Pfizer Inc. (NYSE: PFE) and Cartography Biosciences, Inc. announced a strategic collaboration to discover tumor-selective...
Sanofi’s Redemplo Wins NMPA Approval as First siRNA for Familial Chylomicronemia
Sanofi (NASDAQ: SNY) announced that Redemplo (plozasiran sodium injection), the world’s first small interfering RNA...
Bayer’s Cevatertinib Wins Breakthrough Therapy Designation for HER2‑Mutant NSCLC
Bayer AG (VIE: BAYN) announced that cevatertinib (BAY 2927088) has been granted Breakthrough Therapy Designation (BTD)...
ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement...
HutchMed’s Sovleplenib Meets Phase 3 Primary Endpoint in wAIHA, Targets NDA Filing
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that the Phase 3 registration part of the...
Structure Therapeutics Licenses GLP-1 Patents to Roche for $100 Million Upfront
Structure Therapeutics Inc. (NASDAQ: GPCR) announced that its wholly‑owned subsidiary, Gasherbrum Bio, entered into a...
Sichuan Biokin’s BL-B01D1 ADC Wins Priority Review for ESCC in China
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that iza-bren (izalontamab brengitecan, BL-B01D1), its first‑in‑class...
Ikarovec and VectorBuilder Sign $1 Billion AAV Capsid Deal for AMD Gene Therapy
Ikarovec, a UK‑based gene therapy company, and VectorBuilder, a leader in gene delivery, announced a...